drugset / Trial / NCT02230527

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

NCT02230527

Phase 2/3 Terminated 46 enrolled The Cleveland Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford Stage IV to VI PAD that have undergone a percutaneous transluminal angioplasty (PTA) of the lower extremities in the past 2 weeks.

Timeline

Start
2014-10
Primary completion
2020-05
Completion
2020-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 75 mg Oral
Subject Ticagrelor Small molecule 90 mg Oral